Management ChangeJul 22, 2026, 04:08 PM
NewAmsterdam Pharma COO Douglas Kling Resigns
AI Summary
NewAmsterdam Pharma Company N.V. announced that Douglas Kling will resign from his position as Chief Operating Officer, effective August 14, 2026. Mr. Kling is leaving to take on a chief executive officer role at another clinical-stage biotech company. The company plans to enter into a separation agreement and an advisor agreement with Mr. Kling to ensure a smooth transition, with advisory services focused on the PREVAIL clinical trial of obicetrapib and other clinical programs.
Key Highlights
- Douglas Kling resigned as Chief Operating Officer of NewAmsterdam Pharma.
- His resignation is effective August 14, 2026.
- Mr. Kling is departing to become CEO of another clinical-stage biotech company.
- The company expects to enter into a separation agreement with Mr. Kling.
- An advisor agreement is also expected for transition and advisory services.
- Advisory services will cover the PREVAIL clinical trial of obicetrapib and other programs.
- Material terms of agreements will be disclosed in a future 8-K amendment.
Price Impact
More from NAMS